The failure of torcetrapib: Is there a case for independent preclinical and clinical testing? - Correspondence

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2561-2562

  Shear, Charles L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; TORCETRAPIB;

ACCURACY; BLOOD PRESSURE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUSTRY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; HYPOTHESIS; NOTE; PUBLICATION;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; QUINOLINES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 54349092048     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2561     Document Type: Note

References (6)

1. Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing. Expert Opin Pharmacother 2008;9:875-878
2. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006;113:2936-42
3. Avorn J. Torcetrapib and Atorvastatin - Should Marketing Drive the Research Agenda? N Engl J Med 2005;352:2573-6
4. Shear CL. Torcetrapib and Atorvastatin [letter]. N Engl J Med 2005;353:1527
5. Barter P, Caulfield M, Eriksson M, et al. Effects of torcetrapib on morbidity and mortality in the ILLUMINATE trial. N Engl J Med 2007;357:2109-22
6. DePasquale M, Knight D, Loging W, et al. Mechanistic studies of hemodynamics with a series of cholesterol ester transfer protein inhibitors [abstract 4021]. Circ Res 2007;101(11):1209-10